Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR0230)
Drug Name
Brivaracetam
Synonyms
Brivaracetam; Brivaracetam (USAN/INN); Brivaracetam [USAN:INN]; Brivaracetam. 97%; Briviact; Briviact (TN); MSYKRHVOOPPJKU-BDAKNGLRSA-N; Rikelta; SCHEMBL122081; U863JGG2IA; UCB 34714; UCB-34714; UCB34714; compound 83alpha; (2S)-2-((4R)-2-Oxo-4-propylpyrrolidin-1-yl)butanamide; (2s)-2-[(4r)-2-oxo-4-propylpyrrolidin-1-yl]butanamide; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-4-propyl-, (alphaS,4R)-; 2-(2-oxo-4-propylpyrrolidin-1-yl)butanamide; 357336-20-0; CHEBI:133013; CHEMBL607400; DTXSID00905081; GTPL9041; UNII-U863JGG2IA
Indication Focal seizure [ICD11: 8A68] Approved [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 212.29 Topological Polar Surface Area 63.4
Heavy Atom Count 15 Rotatable Bond Count 5
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 2
Cross-matching ID
PubChem CID
9837243
PubChem SID
14797750 ; 22395457 ; 29195836 ; 44935336 ; 57373479 ; 76633436 ; 96025562 ; 103735408 ; 126671557 ; 134339227 ; 137248619 ; 143057771 ; 144225791 ; 162220569 ; 164151406 ; 179116990 ; 198941312 ; 223668582 ; 224093931 ; 226493435 ; 242768081 ; 252447391
ChEBI ID
CHEBI:133013
CAS Number
357336-20-0
TTD Drug ID
D0CT4D
Formula
C11H20N2O2
Canonical SMILES
CCCC1CC(=O)N(C1)C(CC)C(=O)N
InChI
1S/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9+/m1/s1
InChIKey
MSYKRHVOOPPJKU-BDAKNGLRSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
Brivaracetam metabolite M1a DM001476 N. A. Unclear 1 [2]
Brivaracetam metabolite M1b DM001475
135390938
Oxidation - Hydroxylation 1 [2]
Brivaracetam metabolite M2 DM001477 N. A. Unclear 1 [2]
Brivaracetam metabolite M9 DM001473
59650074
Hydrolysis - Hydrolysis 1 [2]
Brivaracetam metabolite M3 DM001478 N. A. Unclear 2 [2]
Brivaracetam metabolite M4a DM001479 N. A. Unclear 2 [2]
Brivaracetam metabolite M4b DM001474 N. A. Unclear 2 [2]
Brivaracetam metabolite M6 DM001481 N. A. Unclear 2 [2]
Brivaracetam metabolite M8 DM001483 N. A. Unclear 2 [2]
Brivaracetam metabolite M5 DM001480 N. A. Unclear 3 [2]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR002547 Brivaracetam Brivaracetam metabolite M2 Unclear Unclear [2]
MR002548 Brivaracetam Brivaracetam metabolite M1a Unclear Unclear [2]
MR002552 Brivaracetam Brivaracetam metabolite M1b Oxidation - Hydroxylation CYP2C8 ... [2]
MR002556 Brivaracetam Brivaracetam metabolite M9 Hydrolysis - Hydrolysis Unclear [2]
MR002549 Brivaracetam metabolite M1a Brivaracetam metabolite M3 Unclear Unclear [2]
MR002550 Brivaracetam metabolite M1a Brivaracetam metabolite M4a Unclear Unclear [2]
MR002553 Brivaracetam metabolite M1b Brivaracetam metabolite M3 Unclear Unclear [2]
MR002554 Brivaracetam metabolite M1b Brivaracetam metabolite M4b Unclear Unclear [2]
MR002557 Brivaracetam metabolite M9 Brivaracetam metabolite M6 Unclear Unclear [2]
MR002558 Brivaracetam metabolite M9 Brivaracetam metabolite M8 Unclear Unclear [2]
MR002559 Brivaracetam metabolite M9 Brivaracetam metabolite M4a Unclear Unclear [2]
MR002560 Brivaracetam metabolite M9 Brivaracetam metabolite M4b Unclear Unclear [2]
MR002551 Brivaracetam metabolite M4a Brivaracetam metabolite M5 Unclear Unclear [2]
MR002555 Brivaracetam metabolite M4b Brivaracetam metabolite M5 Unclear Unclear [2]
⏷ Show the Full List of 14 MR(s)
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 2B6 (CYP2B6) DME0020 Homo sapiens
CP2B6_HUMAN
1.14.14.1
[2]
Cytochrome P450 2C8 (CYP2C8) DME0018 Homo sapiens
CP2C8_HUMAN
1.14.14.1
[2]
Cytochrome P450 2C9 (CYP2C9) DME0019 Homo sapiens
CP2C9_HUMAN
1.14.14.1
[3]
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[3]
Mephenytoin 4-hydroxylase (CYP2C19) DME0021 Homo sapiens
CP2CJ_HUMAN
1.14.14.1
[2]
References
1 Brivaracetam was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
2 Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos. 2008 Jan;36(1):36-45.
3 Effect of gemfibrozil on the metabolism of brivaracetam in vitro and in human subjects. Drug Metab Dispos. 2012 Aug;40(8):1466-72.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.